Condition
Invasive Pneumococcal Disease, Protection Against
Total Trials
4
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 3 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
2Total
P 2 (1)
P 4 (1)
Trial Status
Completed3
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT03489018Phase 4Completed
The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants
NCT03384589Phase 2CompletedPrimary
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
NCT03815357Completed
What is the Incidence of an Immune Disorder in Children With Invasive Pneumococcal Disease (IPD)?
NCT01694329Unknown
Impact of Introduction of PHiD-CV for Nunavik Children, Quebec, Canada
Showing all 4 trials